E-mail: Ann.janssens@uzleuven.be
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- Final Results from a Phase 4 Open-Label 3-Year Study Evaluating Changes in Bone Marrow (Bm) Morphology in Adult Immune Thrombocytopenia (ITP) Patients (Pts) Receiving the Thrombopoietin Mimetic Romiplostim
- Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP)
- First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy
- Gene Mutations and Treatment Outcome in CLL Patients Treated
- Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study
- IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY
- Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab
- INTERIM RESULTS FROM AN INTERNATIONAL, MULTI-CENTER, SINGLE-ARM STUDY EVALUATING THE SAFETY AND EFFICACY OF ROMIPLOSTIM IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
- NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911)
- Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)
- REDUCED HOSPITALIZATIONS AND BLEEDS IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) RECEIVING ROMIPLOSTIM IN CLINICAL PRACTICE – INTERIM RESULTS FROM A LARGE, EUROPEAN, OBSERVATIONAL STUDY
- Results From a Phase IV Open-Label Study Evaluating Changes In Bone Marrow Morphology In Adult Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim: Analysis Of The 1- and 2-Year Romiplostim Cohorts
- Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)
- ROMIPLOSTIM FOR THE TREATMENT OF ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ROUTINE CLINICAL PRACTICE - INTERIM RESULTS FROM A LARGE, EUROPEAN, OBSERVATIONAL STUDY
- Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice – Interim Results From a Large, European, Observational Study
- SF3B1 MUTATIONS AND OUTCOME IN CLL PATIENTS TREATED WITH CHLORAMBUCIL (CHL) OR OFATUMUMAB-CHL (O+CHL): RESULTS FROM THE PHASE III STUDY COMPLEMENT 1 (OMB110911)
- TELOMERE LENGTH AND POT1 MUTATIONS IN CLL: INCIDENCE, ASSOCIATIONS AND CLINICAL IMPACT IN THE COMPLEMENT 1 TRIAL
- UPDATED RESULTS FROM A LARGE, OBSERVATIONAL STUDY OF PATIENTS (PTS) WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) RECEIVING ROMIPLOSTIM IN EUROPEAN CLINICAL PRACTICE
